Nicole Sweeny
Director · Monopar Therapeutics
- 2025
- Jun 30, 2026
- 10
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Nicole Sweeny files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Venrock Healthcare Capital Partners III, L.P. - $3.69M in KALV purchases and sales in the last 12 months
- Chandler Robinson - $2.56M in MNPR purchases and sales in the last 12 months
- Christopher Yea - $1.23M in KALV purchases and sales in the last 12 months
- Benjamin L. Palleiko - $1.19M in KALV purchases and sales in the last 12 months
- Kim R. Tsuchimoto - $911K in MNPR purchases and sales in the last 12 months
- Raymond Anderson - $703K in MNPR purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Nicole Sweeny?
Nicole Sweeny is a corporate insider, tracked as Director of Monopar Therapeutics (MNPR). InsiderAlpha holds 10 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Nicole Sweeny last file a Form 4?
The most recent primary Form 4 on record is dated 30 June 2026, one of 10 filings going back to 2025.
Has Nicole Sweeny been buying or selling stock?
Recorded transactions: 0 open-market purchases and 7 open-market sales ($285K) across all tracked filings.
